Search
Codexis Inc
CDXSAdd to Watchlist
2.470USD
+0.080+3.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
224.51MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.35%
5 Days
+3.35%
1 Month
-11.79%
6 Months
+53.42%
Year to Date
+51.53%
1 Year
-10.83%
Key Figures
2.400Open
2.500High
1.36MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.49%Turnover Ratio
2.390Prev. Close
2.400Low
2.89MTurnover
LossP/E Static
5.19P/B
0.00%Div Yield TTM
-24.77%ROA
3.87052wk High
1.82Volume Ratio
-65.28MNet Profit
90.89MShares
-0.3495EPS TTM
2.50Beta
-68.90%ROE
0.95852wk Low
4.18%Amplitude
86.46%Gross Margin
224.51MMarket Cap
-3.23Reward/Risk
4.54%Risk Rate
TradingKey Stock Score of Codexis Inc
Currency: USD Updated: 2026-07-02Key Insights
Codexis Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 78 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.58.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Codexis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Codexis Inc Highlights
StrengthsRisks
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Growing
The company is in a growing phase, with the latest annual income totaling USD 70.39M.
Undervalued
The company’s latest PE is -7.07, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 66.34M shares, decreasing 17.31% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 210.50K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
6.583
Target Price
+175.45%
Upside Space
Codexis Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Codexis Inc Info
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Ticker SymbolCDXS
CompanyCodexis Inc
CEOMoore (Alison)
Websitehttps://www.codexis.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Codexis Inc (CDXS)?
The current price of Codexis Inc (CDXS) is 2.47.
What is the symbol of Codexis Inc?
The ticker symbol of Codexis Inc is CDXS.
What is the 52-week high of Codexis Inc?
The 52-week high of Codexis Inc is 3.87.
What is the 52-week low of Codexis Inc?
The 52-week low of Codexis Inc is 0.96.
What is the market capitalization of Codexis Inc?
The market capitalization of Codexis Inc is 224.51M.
Is Codexis Inc (CDXS) currently rated as Buy, Hold, or Sell?
According to analysts, Codexis Inc (CDXS) has an overall rating of Buy, with a price target of 6.58.
What is the Earnings Per Share (EPS TTM) of Codexis Inc (CDXS)?
The Earnings Per Share (EPS TTM) of Codexis Inc (CDXS) is -0.50.